Trial Profile
International, Multicenter, Randomized, Double Blind, Active-controlled, Parallel-group Phase III Study of Narlaprevir/Ritonavir and Pegylated Interferon/Ribavirin in 2 Patient Populations - naïve and Treatment Failure Patients With Genotype 1 Chronic Hepatitis C
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Narlaprevir (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PIONEER
- Sponsors R-Pharm
- 13 Apr 2018 New trial record
- 06 Jun 2016 Status changed to completed, according to a R-Pharm media release.